Eotaxin-2 in sputum cell culture to evaluate asthma inflammation

European Respiratory Journal

Volumn 29, Issue 3, 2007, Pages 489-495

  Scheicher, M E ^a   Teixeira, M M ^b   Cunha, F Q ^a   Teixeira Jr , A L ^b   Filho, J T ^a   Vianna, E O ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

Asthma; Cell culture; Inflammatory mediatros; Sputum; Steroid

Indexed keywords

BRONCHODILATING AGENT; CHEMOKINE; CORTICOSTEROID; EOTAXIN 2; INTERLEUKIN 13; INTERLEUKIN 1BETA; INTERLEUKIN 8; PREDNISONE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADULT; ARTICLE; ASTHMA; CELL CULTURE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; EOSINOPHIL COUNT; FEMALE; HUMAN; INFLAMMATORY CELL; MALE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SPUTUM CULTURE; SUPERNATANT;

EID: 33847765099     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.00060205     Document Type: Article

References (38)

1. Spahn J, Covar R, Stempel DA. Asthma: addressing consistency in results from basic science, clinical trials, and observational experience. J Allergy Clin Immunol 2002; 109: Suppl. 5, 490S-502S.
2. Maddox L, Schwartz DA. The pathophysiology of asthma. Annu Rev Med 2002; 53: 477-498.
3. Zlotnik A, Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity 2000; 12: 121-127.
4. Teran LM. CCL chemokines and asthma. Immunol Today 2000; 21: 235-242.
5. Rojas-Ramos E, Avalos AF, Perez-Fernandez L, Cuevas-Schacht F, Valencia-Maqueda E, Teran LM. Role of the chemokines RANTES, monocyte chemotactic proteins-3 and -4, and eotaxins-1 and -2 in childhood asthma. Eur Respir J 2003; 22: 310-316.
6. Ying S, Meng O, Zeibecoglou K, et al. Eosinophil chemotactic chemokines (eotaxin, eotaxin-2, RANTES, monocyte chemoattractant protein-3 (MCP-3), and MCP-4), and C-C chemokine receptor 3 expression in bronchial biopsies from atopic and nonatopic (Intrinsic) asthmatics. J Immunol 1999; 163: 6321-6329.
7. Teran LM, Noso N, Carroll M, Davies DE, Holgate S, Schroeder JM. Eosinophil recruitment following allergen challenge is associated with the release of the chemokine RANTES into asthmatic airway. J Immunol 1996; 157: 1806-1812.
8. Lamkhioued B, Renzi PM, Abi-Younes S, et al. Increased expression of eotaxin in bronchoalveolar lavage and airways of asthmatics contributes to the chemotaxis of eosinophils to the site of inflammation. J Immunol 1997; 159: 4593-4601.
9. Lamkhioued B, Garcia-Zepeda EA, Abi-Younes S, et al. Monocyte chemoattractant protein (MCP)-4 expression in the airways of patients with asthma. Induction in epithelial cells and mononuclear cells by proinflammatory cytokines. Am J Respir Crit Care Med 2000; 162: 723-732.
10. Miotto D, Christodoulopoulos P, Olivenstein R, et al. Expression of IFN-γ-inducible protein; monocyte chemotactic proteins 1, 3, and 4; and eotaxin in Thl- and Th2-mediated lung diseases. J Allergy Clin Immunol 2001; 107: 664-670.
11. Vignola AM, Rennard SI, Hargrave FE, et al. Standardised methodology of sputum induction and processing. Future directions. Eur Respir J 2002; 20: Suppl. 37, 51S-55S.
12. Kips JC, Inman MD, Jayaram L, et al. The use of induced sputum in clinical trials. Eur Respir J 2002; 20: Suppl. 37, 47S-50S.
13. Djukanovic R, Sterk PJ, Fahy JV, Hargreave FE. Standardised methodology of sputum induction and processing. Eur Respir J 2002; 20: Suppl. 37, 1S-2S.
14. Pin I, Gibson PG, Kolendowicz R, et al. Use of induced sputum cell counts to investigate airway inflammation in asthma. Thorax 1992; 47: 25-29.
15. Corrigan CJ, Bungre JK, Assoufi B, Cooper AE, Seddon H, Kay AB. Glucocorticoid resistant asthma: T-lymphocyte steroid metabolism and sensitivity to glucocorticoids and immunosuppressive agents. Eur Respir J 1996; 9: 2077-2086.
16. Vianna EO, Westcott J, Martin RJ. The effects of upper respiratory infection on T-cell proliferation and steroid sensitivity of asthmatics. J Allergy Clin Immunol 1998; 102: 592-597.
17. Kraft M, Vianna E, Martin RJ, Leung DY. Nocturnal asthma is associated with reduced glucocorticoid receptor binding affinity and decreased steroid responsiveness at night. J Allergy Clin Immunol 1999; 103: 66-71.
18. Bettiol J, Sele J, Henket M, et al. Cytokine production from sputum cells after allergenic challenge in IgE-mediated asthma. Allergy 2002; 57: 1145-1150.
19. Liu LY, Swensen CA, Kelly EA, Kita H, Busse WW. The relationship of sputum eosinophilia and sputum cell generation of IL-5. J Allergy Clin Immunol 2000; 106: 1063-1069.
20. Komai-Koma M, McKay A, Thomson L, et al. Immuno-regulatory cytokines in asthma: IL-15 and IL-13 in induced sputum. Clin Exp Allergy 2001; 31: 1441-1448.
21. Hamzaoui A, Brahim MB, Zhioua A, Ayed K, Hamzaoui K. Inflammatory response in induced sputum mononuclear cells from patients with acute exacerbation of asthma. Mediators Inflamm 2000; 9: 147-153.
22. Boniface S, Koscher V, Mamessier E, et al. Assessment of T lymphocyte cytokine production in induced sputum from asthmatics: a flow cytometry study. Clin Exp Allergy 2003; 33: 1238-1243.
23. ACCP-ATS joint Committee on Pulmonary Nomenclature, Pulmonary terms and symbols. Chest 1975; 67: 5833-5893.
24. Paggiaro PL, Chanez P, Holz O, et al. Sputum induction. Eur Respir J 2002; 20: Suppl. 37, 3S-8S.
25. Pizzichini E, Pizzichini MM, Leigh R, Djukanovic R, Sterk PJ. Safety of sputum induction. Eur Respir J 2002; 20: Suppl. 37, 9S-18S.
26. Griffiths-Johnson DA, Collins PD, Rossi AG, Jose PJ, Willians TJ. The chemokine, eotaxin, activates guinea-pig eosinophils in vitro and causes their accumulation into the lung in vivo. Biochem Biophys Res Commun 1993; 197: 1167-1172.
27. Jose PJ, Griffiths-Johnson DA, Collins PD, et al. Eotaxin: a potent eosinophil chemoattractant cytokine detected in a guineapig model of allergic airways inflammation. J Exp Med 1994; 179: 881-887.
28. Mattoli S, Stacey MA, Sun G, Bellini A, Marini M. Eotaxin expression and eosinophilic inflammation in asthma. Biochem Biophys Res Commun 1997; 236: 299-301.
29. Rankin SM, Conroy DM, Williams TJ. Eotaxin and eosinophil recruitment: implications for human disease. Mol Med Today 2000; 6: 20-27.
30. Forssmann U, Uguccioni M, Loetscher P, et al. Eotaxin-2, a novel CC chemokine that is selective for the chemokine receptor CCR3, and acts like eotaxin on human eosinophil and basophil leukocytes. J Exp Med 1997; 185: 2171-2176.
31. White JR, Imburgia C, Dul E, et al. Cloning and functional characterization of a novel human CC chemokine that binds to the CCR3 receptor and activates human eosinophil. J Leukoc Biol 1997; 62: 667-675.
32. Ying S, Robinson DS, Meng O, et al. CC chemokines in allergen-induced late-phase cutaneous responses in atopic subjects: association of eotaxin with early 6-hour eosinophils, and of eotaxin-2 and monocyte chemoattractant protein-4 with the later 24-hour tissue eosinophilia, and relationship to basophils and other CC chemokines (monocyte chemoattractant protein-3 and RANTES). J Immunol 1999; 163: 3976-3994.
33. Jatakanon A, Kharitonov S, Lim S, Barnes PJ. Effect of differing doses of inhaled budesonide on markers of airway inflammation in patients with mild asthma. Thorax 1999; 54: 108-114.
34. Leung DY, De Castro M, Szefler SJ, Chrousos GP. Mechanisms of glucocorticoid-resistant asthma. Ann N Y Acad Sci 1998; 840: 735-746.
35. Walsh SD, Grant IWB. Corticosteroids in the treatment of asthma. BMJ 1966; 2: 796-807.
36. Mukaida N, Morita M, Ishikawa Y, et al. Novel mechanism of glucocorticoid-mediated gene repression. Nuclear factor-kappa B is target for glucocorticoid-mediated interleukin-8 gene repression. J Biol Chem 1994; 269: 13289-13295.
37. Kelley J. Cytokines of the lung. Am Rev Respir Dis 1990; 141: 765-788.
38. Hadjicharalambous C, Dent G, May RD, et al. Measurement of eotaxin (CCL11) in induced sputum supernatants: validation and detection in asthma. J Allergy Clin Immunol 2004; 113: 657-662.